| Identification | Back Directory | [Name]
2,4,6(1H,3H,5H)-Pyrimidinetrione, 1-[2-(3-chlorophenyl)ethyl]-3-cyclopentyl- | [CAS]
1391385-57-1 | [Synonyms]
CaV1.3 antagonist-1
2,4,6(1H,3H,5H)-Pyrimidinetrione, 1-[2-(3-chlorophenyl)ethyl]-3-cyclopentyl- | [Molecular Formula]
C17H19ClN2O3 | [MOL File]
1391385-57-1.mol | [Molecular Weight]
334.8 |
| Chemical Properties | Back Directory | [Boiling point ]
469.3±47.0 °C(Predicted) | [density ]
1.335±0.06 g/cm3(Predicted) | [storage temp. ]
4°C, protect from light | [solubility ]
DMSO : 100 mg/mL (298.69 mM; Need ultrasonic) | [form ]
Solid | [pka]
6.10±0.40(Predicted) | [color ]
White to light yellow |
| Hazard Information | Back Directory | [Uses]
CaV1.3 antagonist-1 is a potent and highly selective CaV1.3 L-type calcium channel (LTCC) antagonist with an IC50 of 1.7 μM. CaV1.3 antagonist-1 inhibits CaV1.3 LTCC >600-fold more potently than CaV1.2 LTCC. CaV1.3 antagonist-1, a cyclopentyl derivative, has the potential for Parkinson's disease research[1]. | [IC 50]
CaV1.3: 1.7 μM (IC50) | [storage]
4°C, protect from light | [References]
[1] Soosung Kang, et al. CaV1.3-selective L-type calcium channel antagonists as potential new therapeutics for Parkinson's disease. Nat Commun. 2012;3:1146. DOI:10.1038/ncomms2149 |
|
|